According to a recent market study published by Growth Market Reports, titled, “Global Myc Proto-Oncogene Protein Market is segmented into by myelocytomatosis (Myc) type, by end-user, by distribution channel and by region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 131.7 million in 2022 and is expected to grow at a growth rate of 7.4% by the year 2031.

The Myc proto-oncogene protein, also known as Myc protein, is a transcription factor or a protein coding gene. It plays a crucial role in various cellular processes including, cell cycle progression, apoptosis, cellular metabolism and biosynthesis, adhesion, and mitochondrial biogenesis and cellular transformation.

Get Sample Report @ https://growthmarketreports.com/request-sample/6641

Cell cycle progression: Myc promotes cell division by activating the transcription of genes involved in DNA replication and cell growth.

Cell differentiation: Myc regulates cell differentiation, which is the process by which immature cells become specialized cells with specific functions.

Metabolism: Myc influences cellular metabolism by regulating the expression of genes involved in energy production and utilization.

Based on myelocytomatosis (Myc) type, the global Myc proto-oncogene protein market is divided into c-Myc, L-Myc, S-Myc, and N-Myc. The c-Myc segment is estimated to hold a significant share of the market during the forecast period, as it is essential for embryonic development and the maintenance of normal tissues. The N-Myc segment is estimated to hold a considerable share of the market during the forecast period, as it plays a critical role in neurogenesis (neuron formation) and brain development.

On the basis of end-user, the global Myc proto-oncogene protein market is segmented into research laboratories, pharmaceutical companies, contract research organizations, and others. The research laboratories segment is expected to register a considerable CAGR in the coming years, as Myc is crucial in studying the cell cycle, the process of cell growth and division. The pharmaceutical companies segment is anticipated to expand at a substantial CAGR during the forecast period, as Myc offers promising avenues in developing novel cancer therapies.

Based on distribution channel, the market is bifurcated into direct and indirect. The direct segment is projected to expand at a rapid pace during the forecast period, as it is convenient to sell Myc proto-oncogene protein directly to research institutes, pharmaceutical companies, and other end-users. The indirect segment is expected to hold a considerable share of the market during the forecast period, as intermediaries play a crucial role in connecting manufacturers with end-users.

The outbreak of Coronavirus disease in 2019 (COVID-19) hampered the global economy, created global interdependence, and challenged the governments of various nations. Numerous industries across the globe, including the healthcare & research industry, had significantly affected, due to the COVID-19 pandemic. The pandemic hindered the Myc proto-oncogene protein market, affecting both production and demand. The pandemic caused massive disruptions in supply chains, affecting the production and distribution of Myc proto-oncogene protein.

The Future of the Myc Proto-Oncogene Protein Market:

The future of the Myc proto-oncogene protein market holds immense potential for advancements and contributions to cancer treatment. The COVID-19 pandemic presented both challenges and opportunities in the Myc proto-oncogene protein market. The market was hampered during the initial phase of the pandemic due to supply chain disruptions. However, continued research holds the promise of significant breakthroughs in Myc-targeted therapies.

COVID-19 had a significant impact on the Myc proto-oncogene protein market. However, the market is expected to grow significantly in the coming years, as Myc-targeted therapies have become effective and accessible.

Emergency lockdowns and several restrictions led to temporary delays in Myc-related research projects. Laboratories faced closures, supply chain disruptions, and limitations on collaborative activities. The economic downturn caused by the pandemic led to potential funding reallocations and investment uncertainties, impacting some research endeavors and the development pipeline of Myc-targeted therapies.

Market Key Developments

On February 5, 2024, GenScript announces the initiation of the GenScript Life Science Research Grant Project. This groundbreaking initiative is a testament to advancing the frontiers of science by supporting innovative projects across a range of life science fields, including but not limited to those of the following: Gene and Cell Therapy Development, Antibody Drug Discovery, Vaccine Development, Diagnostic Development, and Plant Sciences Research.

On August 8, 2023, GenScript has ramped up the production of complex and modified peptides at its state-of-the-art cGMP manufacturing facility in Zhenjiang, China. A new, one-stop service offers neoantigen and peptide active pharmaceutical ingredients (API) adapted for large-scale manufacturing. The company also offers expert consulting support for CMC filing documents and the development of global regulatory strategies for new peptide drugs.

The players in the Global Myc Proto-Oncogene Protein Market include Abcam plc.; Active Motif; Biosensis Pty Ltd; Creative Biolabs.; CUSABIO TECHNOLOGY LLC; GenScript; LifeSpan BioSciences, Inc; Merck KGaA; Novus Biologicals; OriGene Technologies, Inc.; Proteintech Group, Inc.; RayBiotech Life, Inc.; and Others.

Report Metric

Details

Market Value in 2023

USD 131.7 Million

Market Growth Rate (from 2023 to 2031)

 7.4%

Historical Data

2017 & 2021

Base Year

2022

Forecast Period

2023 – 2031

Units Considered

Value (USD Million)

Market Segments

By Myelocytomatosis (Myc) Type, By End-User and  By Distribution Channel

Key Companies Profiled

Abcam plc.; Active Motif, Biosensis Pty Ltd; Creative Biolabs.; CUSABIO TECHNOLOGY LLC; GenScript; LifeSpan BioSciences, Inc.; Merck KGaA; Novus Biologicals; OriGene Technologies, Inc.; Proteintech Group, Inc.; RayBiotech Life, Inc.; and Others.

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

Target Audience:

  • Supply-side: Manufacturer, Suppliers and End-users.

  • Demand Side: Research Laboratories, Pharmaceutical Companies, Contract Research Organizations, and Others.